Jun 15, 2020
Medicure Announces Top Line Data from FABOLUS-FASTER Trial With AGGRASTAT® will be Presented at the PCR e-Course, Late Breaking Trial Sessions, June 27, 2020
Jun 15, 2020
Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients
Jun 03, 2020
EULAR 2020: Lilly Shares New Data for Olumiant® in Rheumatoid Arthritis and Systemic Lupus Erythematosus
May 29, 2020
Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery
Apr 23, 2020
United Therapeutics Announces Additional Results From FREEDOM-EV Study Showing The Hemodynamic And Risk Status Reduction Benefits Of Orenitram Treatment In Patients With Pulmonary Arterial Hypertension
Apr 03, 2020
Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension (PAH) with Oral Prostacyclin Pathway Agents (PPAs) Published in CHEST Journal
Mar 16, 2020
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
Mar 05, 2020
Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class And Segment Forecasts, 2020 - 2027
Feb 28, 2020
HUYA Bioscience International® Announces the Successful Completion of Phase 1 Trial of HBI-3000
Feb 28, 2020
HUYA Bioscience International® Announces the Successful Completion of Phase 1 Trial of HBI-3000
Dec 24, 2019
Correvio Receives Complete Response Letter From U.S. FDA for Brinavess and Provides Update on Recent Events
Dec 17, 2019
Medicure Announces the Completion of Shortened AGGRASTAT® Versus Integrilin® in Percutaneous Coronary Intervention (SAVI-PCI) Study
Dec 12, 2019
Medicure Announces Completion of Enrollment for FABOLUS-FASTER, Phase 4 Clinical Trial of Aggrastat (Tirofiban Hydrochloride) Injection VS Kengreal (Cangrelor) in Patients Undergoing Percutaneous Coronary Intervention (PCI)
Dec 11, 2019
Correvio Announces Intention to Explore Strategic Alternatives to Maximize Stakeholder Value
Dec 06, 2019
Curis Announces Positive Safety, Tolerability and Pharmacokinetic Data in Ongoing Phase 1 Study of Fimepinostat in Combination with Venetoclax
Dec 05, 2019
Medicure Files Patent Infringement Action
Sep 26, 2019
FDA approves treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to eight weeks
Sep 03, 2019
Rho kinase inhibitor, "Ripasudil Hydrochloride Hydrate" IND application for Phase 2 clinical study in the United States Indication for Corneal Endothelial Diseases [Developmental code: K-321]
Aug 21, 2019
Medicure Announces Settlement of Patent Infringement Action
Aug 08, 2019
Correvio to Report Second Quarter 2019 Financial Results